BCDA - BioCardia, Inc.

1.18
-0.025   -2.119%

Share volume: 102,411
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.19%

PREVIOUS CLOSE
CHG
CHG%
$1.20
-0.03
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
31%
Profitability 43%
Dept financing 20%
Liquidity 59%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-12.59%
1 Month
-6.35%
3 Months
-17.48%
6 Months
-43.54%
1 Year
-54.96%
2 Year
175.70%
Key data
Stock price
$1.18
P/E Ratio 
0.00
DAY RANGE
$1.14 - $1.21
EPS 
-$2.07
52 WEEK RANGE
$1.00 - $3.20
52 WEEK CHANGE
-$53.54
MARKET CAP 
7.484 M
YIELD 
N/A
SHARES OUTSTANDING 
10.613 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
3.53
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$80,443
AVERAGE 30 VOLUME 
$72,973
Company detail
CEO: Peter Alan Altman, PhD
Region: US
Website: biocardia.com
Employees: 40
IPO year: 2008
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

BioCardia, Inc. develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy.

Recent news